This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
HSIC or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
Merit Medical (MMSI) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.
SmileDirectClub (SDC) Down 25.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
SmileDirectClub (SDC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merit Medical (MMSI) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merit Medical's (MMSI) New Launch to Boost its Product Suite
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly enhance patient outcomes.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
CVS Health's (CVS) New Acquisitions Aid, Cost Woes Linger
by Zacks Equity Research
CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.
IDEXX (IDXX) Global Sales, Instrument Placement Robust
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, primarily aided by a gain in CAG and Water businesses.
MMSI vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
MMSI vs. WST: Which Stock Is the Better Value Option?
Merit Medical (MMSI) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in its Cardiovascular segment and the majority of product categories within its Cardiovascular unit.
Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 17.91% and 1.26%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Walgreens' (WBA) New Partnerships Aid, Margin Pressure Ails
by Zacks Equity Research
Walgreens Boots (WBA) raises its U.S. Healthcare target, including fiscal 2025 sales goal.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Staar Surgical (STAA) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of -6.67% and 0.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Base Business Growth Robust, Volume Up
by Zacks Equity Research
Quest Diagnostics (DGX) starts to benefit from incentives related to these value-based contracts, which help demonstrate the value of these strategic relationships.
Medtronic (MDT) Receives CE Mark Approval For Aurora System
by Zacks Equity Research
Medtronic (MDT) Aurora EV-ICD system indicated for patients at risk of life-threatening arrhythmias.
MedTech Stocks' Q4 Earnings on Feb 22: FMS, GKOS & More
by Debanjana Dey
MedTech companies' Q4 results are likely to reflect strength in customer demand. Let's see how FMS, GKOS, MMSI and DVA are placed ahead of their earnings releases.
Reasons to Retain Patterson Companies (PDCO) Stock Now
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) strong product line.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) strong performance across its Animal Safety and Food Safety segments.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) owing to continued growth in the Diabetes business.
Edwards Lifesciences (EW) Gains on Innovation, Margin Growth
by Zacks Equity Research
In Edwards Lifesciences' (EW) Smart Recovery portfolio, the adoption of FloTrac and ClearSight sensors remains strong.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues benefiting from its commitment to understand the venous system. However, dependency on the wide adoption of products is a concern.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
Boston Scientific (BSX) Gains From New Buyouts, Cost Woes Stay
by Zacks Equity Research
Boston Scientific's (BSX) EMEA business grows above market, supported by the company's ongoing investments in emerging markets.